Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Ulrich

Facial Plastic Surgery Grand Blanc, MI Doctor of Osteopathy

NPI 1366554677 CMS profile 334068

9463 Holly Rd, Suite 100, Grand Blanc, MI 48439

Open in the dashboard

General payments

$6,907

72 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Ulrich of Grand Blanc, MI is reported in the CMS Open Payments database as having received $6,907 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Facial Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $116 3
2024 General $69 3
2023 General $756 12
2022 General $2,369 26
2021 General $869 6
2020 General $951 6
2019 General $1,776 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Ulrich
  • Facial Plastic Surgery median
  • Middle half of Facial Plastic Surgery
  • National median

In program year 2025, general payments to John Ulrich were reported at $116. Among 437 Facial Plastic Surgery profiles paid that year, the median was $270 and the middle half received between $116 and $579.

Show as a table
Year John Ulrich Facial Plastic Surgery median Middle half National median
2019 $1,776 $225 $92–$651 $163
2020 $951 $132 $45–$323 $114
2021 $869 $186 $67–$558 $132
2022 $2,369 $218 $83–$594 $149
2023 $756 $237 $94–$564 $160
2024 $69 $233 $104–$575 $164
2025 $116 $270 $116–$579 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,747 20 payments
  2. Medical Device Business Services, Inc. $1,759 9 payments
  3. Medtronic, Inc. $1,138 16 payments
  4. Acclarent, Inc $761 16 payments
  5. OptiNose US, Inc. $149 2 payments
  6. Aerin Medical Inc. $129 1 payment
  7. Integra LifeSciences Corporation $103 4 payments
  8. Intersect ENT, Inc. $48 1 payment
  9. Amgen Inc. $34 1 payment
  10. Covidien LP $22 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,907 22 payments
  2. Food and Beverage $1,966 49 payments
  3. Education $34 1 payment
Products named General payments · program years 2019–2025
  1. ENTELLUS - XPRESS ENT DILATION SYSTEM $1,678 12 payments
  2. STEALTHSTATION S8 PLATFORM $1,138 16 payments
  3. XPRESS ENT DILATION SYSTEM $795 4 payments
  4. Acclarent Aera $253 6 payments
  5. ACCLARENT NAVWIRE Sinus Navigation Guidewire $200 2 payments
  6. Relieva Spinplus $171 1 payment
  7. SCOPIS ENT $153 1 payment
  8. Xhance $149 2 payments
  9. VIVAER STYLUS $129 1 payment
  10. RHINAER STYLUS $129 1 payment
  11. Other $785 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

930

Median for Otolaryngology: 297

Drug cost

$10,909

Median for Otolaryngology: $6,314

Branded share of claims

11.8%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluticasone Propionate Generic 179 $2,140
Ipratropium Bromide Generic 65 $1,775
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 13 $1,645
Fluocinolone Acetonide Oil Generic 25 $808
Ofloxacin Generic 60 $752
Doxycycline Hyclate Generic 66 $501
Mupirocin Generic 79 $491
Prednisone Generic 89 $471
Cefdinir Generic 20 $452
Cephalexin Generic 56 $379

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$86,448

Medicare's payments for the services billed

Medicare patients

187

Average age 76

Services billed

708

101 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 53%
Ischemic heart disease 28%
Diabetes 24%
Chronic kidney disease 24%
COPD 22%
Depression 21%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Facial Plastic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record